PUBLISHER: The Business Research Company | PRODUCT CODE: 1760679
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760679
Personalized psychiatry is an individualized approach to mental health care that combines genetic, biological, environmental, and clinical information to customize diagnosis, treatment planning, and therapeutic strategies for each patient. This approach aims to improve treatment effectiveness, reduce adverse effects, and enable early intervention by aligning psychiatric care with the unique biological and psychological profile of the individual.
The main categories of personalized psychiatry include products, services, and software. Personalized psychiatry products consist of specialized medical tools, diagnostics, and therapeutic solutions developed to support individualized mental health treatment based on a person's genetic, biological, and behavioral traits. Key technologies in this field include genetic testing, artificial intelligence, neurostimulation technology, and digital therapeutics, which are applied in the management of conditions such as depression, anxiety disorders, bipolar disorder, schizophrenia, and attention-deficit hyperactivity disorder (ADHD). These solutions are used across various settings including clinics, hospitals, research institutes, and homecare environments.
The personalized psychiatry market research report is one of a series of new reports from The Business Research Company that provides personalized psychiatry market statistics, including personalized psychiatry industry global market size, regional shares, competitors with a personalized psychiatry market share, detailed personalized psychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the personalized psychiatry industry. This personalized psychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The personalized psychiatry market size has grown rapidly in recent years. It will grow from $5.69 billion in 2024 to $6.53 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth during the historic period can be attributed to increased awareness of mental health, a rising prevalence of psychiatric disorders, growing demand for personalized healthcare, higher healthcare expenditures, and improved access to and affordability of healthcare services.
The personalized psychiatry market size is expected to see rapid growth in the next few years. It will grow to $11.24 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period is driven by the expanding adoption of digital therapeutics, a growing need for remote patient monitoring, increasing demand for mental health solutions in the post-COVID-19 landscape, rising government and private sector investments in mental health, and a push for more accessible mental healthcare services. Key trends expected during this period include greater use of artificial intelligence in mental health diagnostics, the rising popularity of telepsychiatry and online consultations, integration of blockchain for securing mental health data, increased use of virtual reality (VR) in therapeutic applications, and the expansion of wearable devices for mental health monitoring.
The growing prevalence of mental health issues is expected to drive the expansion of the personalized psychiatry market. Mental health issues encompass a wide range of conditions that impact a person's emotional, psychological, and social well-being. The increase in these issues is largely attributed to rising stress levels and lifestyle-related challenges, often driven by fast-paced work environments, poor work-life balance, and limited coping mechanisms. Personalized psychiatry addresses these concerns by offering tailored treatment plans based on an individual's unique biological, psychological, and lifestyle factors. This approach enhances the effectiveness of care by reducing trial and error in treatment, leading to quicker recovery and improved outcomes. For example, in 2022, the National Institute of Mental Health, a U.S.-based federal research agency, estimated that 59.3 million adults aged 18 and older in the United States had any mental illness (AMI), accounting for 23.1% of the total adult population. Therefore, the rise in mental health issues is driving the growth of the personalized psychiatry market.
Leading companies in the personalized psychiatry market are developing advanced services, such as personalized telepsychiatry, to improve access to individualized mental health care through flexible, patient-centered service models. Personalized telepsychiatry is a remote mental healthcare approach that delivers customized psychiatric evaluation and treatment based on an individual's unique genetic, environmental, and lifestyle factors using digital communication platforms. For example, in April 2025, Alice's Psychiatry & Wellness, a U.S.-based psychiatry and wellness service provider, launched a clinic to offer compassionate, personalized psychiatric care to adults across multiple states via both in-person and telepsychiatry services. This clinic integrates pharmacogenetic testing to tailor psychiatric medications according to each patient's genetic profile, enhancing treatment effectiveness and minimizing adverse effects. By leveraging virtual platforms and providing continuous care from dedicated providers, the clinic ensures accessible, consistent, and comprehensive mental health support, fully aligned with the principles of personalized psychiatry.
In March 2025, April Health Inc., a U.S.-based behavioral health company, merged with Wysa Ltd. for an undisclosed amount. This merger aims to combine Wysa's AI-driven mental health support with April Health's virtual behavioral health services, enhancing access to personalized behavioral healthcare through primary care providers. Wysa Ltd., a U.S.-based digital mental health company, utilizes artificial intelligence (AI) to deliver personalized, evidence-based psychiatric support.
Major players in the personalized psychiatry market are Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb, Medtronic Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim, Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Neurocrine Biosciences, Spring Health, Neumora Therapeutics Inc., Atai Life Sciences, Valera Health, Compass Pathways, Genomind, Woebot Health, BrightQuest Treatment Centers, Meru Health, Alto Neuroscience, Arcara Personalized Psychiatry, GreyBird Ventures, Mind Sync Therapeutics, Starling Minds, and HMNC Holding GmbH.
North America was the largest region in the personalized psychiatry market in 2024. The regions covered in personalized psychiatry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the personalized psychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The personalized psychiatry market consists of revenues earned by entities by providing services such as remote patient monitoring services for mental health, mental health coaching programs, medication management support, lifestyle and behavioral modification programs, cognitive assessment services, and in-home psychiatric care. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized psychiatry market also includes sales of biomarker-based diagnostic assays, neurofeedback equipment, point-of-care mental health diagnostic tools, personalized supplement formulations, and biosensor-integrated monitoring tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Personalized Psychiatry Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on personalized psychiatry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for personalized psychiatry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The personalized psychiatry market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.